ceo seri turn corner
durabl
appreci support
institut investor all-america
research survey request ballot
work transform organ growth profil
deliv consist perform recent trend support
chang see multipl underappreci driver
growth margin mix remain overweight
ceo seri liam kelli ceo seri weekli
call ceo across medic devic field discuss key structur dynam
invest debat recent host liam kelli presid ceo
theme discuss focus transform
past sever year materi acquisit fundament shift
compani organ profil think top-line growth look sustain
combin margin expans opportun drive mid-teen
earn growth start look durabl improv
organ growth momentum last two quarter busi profil
differ pipelin offer option margin thesi remain
intact suggest aggreg well posit
organ eventu durabl consist perenni
investor concern given multipl issu core busi ex vsi
neotract quarterli volatil see year itch sinc
seen much consist perform busi given
divestitur etc reduc distributor relianc come
time na discuss emphas compani fastest
growth busi neotract intervent asia go distributor
revenu area
possess market domin strong ip manufactur advantag increas
confid futur growth durabl remain confid reach
top end organ growth guidanc impli pt
momentum acceler discuss dynam lead acceler
neotract ampl runway growth manag initi guid neotract
revenu growth rais deliv y/i growth
guidanc like conserv given neotract deliv
growth ahead expect ii rep hire begin contribut
manag expect steadi cadenc hire
year iii commentari dtc market campaign suggest initi
medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
gener result target market plan broader roll-out
region iv neotract anniversari suppli disrupt second half
eas compar manag see rezum competit
headwind given reimburs see compani see rezum
target surgic bph popul vs neotract target drug
drop-out see potenti guidanc rais neotract earli
model organ growth growth
pipelin offer option reflect lrp
manta manag market estim compar
assumpt laid see larg bore larg opportun
said estim includ impella patient dilig
suggest asp manta track closer vs
assum manag expect nomin contribut
model manta potenti gener
revenu penetr ad pt growth
repla percuv lrp assumpt
respect assum market penetr repla bla
submiss track initi market penetr focu
militari market revenu contribut expect
percuv enter full market releas remain show
stori although manag commentari suggest posit surgeon
feedback sage recent see
distributor direct dtd convers remain opportun lrp
assum addit convers increment convers beyond
announc prior analyst day allow increas revenu
visibl lift gross margin note total revenu
sold distributor least
repres convers opportun bp per year
aggreg opportun repres pt upsid includ
lrp increas confid sustain profil look
risk adjust toward upper end
balanc sheet like back debat later year de-lever
limit deploy tuck-in mainli manta allow reach
net leverag net leverag approach manag
state capac neotract/vsi size deal feel urgenc
continu disciplin view scale
necessari shift weight averag market growth rate wamgr higher
compani proven modest deploy manta recent
up-front addit growth see regard end market
manag state comfort exist busi segment feel
need add anoth leg stool henc strateg prioriti focu
build exist segment consist depth breadth view
 strategi devic
respiratori asset addit subtract commentari notabl
vocal certain respiratori asset compris
revenu within segment non-strateg divest slower
growth asset equal power shift faster
wamgr area asset sale would shift organ growth profil
higher bp
comfort sustain mid-teen earn growth
forese futur consist past three year
gross margin lrp call bp expans ratabl
bp per year analysi suggest
neotract exhibit announc cost initi bp
program alon deliv object see potenti upsid
manta gm addit dtd convers neither
includ lrp mix dynam intervent asia
carri vs current corpor note everi pt
gm expans drive pt ep growth
oper margin margin target impli bp
expans oper margin guidanc impli
bp expans midpoint impli margin expans like
back-half weight lrp bp per year
manag convey confid step-up expans
driven gm drop ii pull forward neotract
invest bp iii neotract becom accret oper
margin iv previous discuss restructur initi
note pt om expans drive pt ep growth
reaffirm confid thesi remain overweight overweight thesi
predic above-p revenu ep growth profil
support premium valuat larg cap peer result signal
strong start year deliv pt momentum acceler buck
deceler trend seen across broader devic see momentum
begin year combin recent ceo convers left us confid
top-line acceler model high end manag
organ growth guidanc variou margin expans opportun driven
sale mix restructur program drive mid-teen earn growth
forese futur model ep growth
manag guidanc price target base
ep line high growth larg cap devic peer abbott boston
replay inform dial-in number
confer id avail may
price target base ep line high growth larg
cap devic peer abbott boston justifi compar top bottom line
growth rate organ growth acceler driven
neotract vascular solut vidacar new product adopt core
higher growth ex us margin expand driven restructur
activ better mix shift drive mid high teen ep growth base case
valuat base ep line high growth larg cap devic
peer justifi compar top bottom line growth rate
risk price target includ materi delay reach long
term margin target core busi restructur program fall behind schedul
ii neotract competit intensifi rezum success take market share
offic set iii new product launch acquisit fail deliv meaning
